Fuzeon is a drug owned by Hoffmann La Roche Inc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 07, 2015. Details of Fuzeon's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6475491 | Treatment of HIV and other viral infections using combinatorial therapy |
Jun, 2015
(9 years ago) |
Expired
|
| US6133418 | Synthetic peptide inhibitors of HIV transmission |
Nov, 2014
(10 years ago) |
Expired
|
| US5464933 | Synthetic peptide inhibitors of HIV transmission |
Jun, 2013
(11 years ago) |
Expired
|
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Fuzeon and ongoing litigations to help you estimate the early arrival of Fuzeon generic.
Fuzeon's Litigations
Fuzeon been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 23, 1999, against patent number US5464933. The petitioner , challenged the validity of this patent, with BOLOGNESI as the respondent. Click below to track the latest information on how companies are challenging Fuzeon's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US5464933 | April, 1999 |
Decision
(23 Apr, 1999) | BOLOGNESI | |
US patents provide insights into the exclusivity only within the United States, but Fuzeon is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Fuzeon's family patents as well as insights into ongoing legal events on those patents.
Fuzeon's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Fuzeon's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 07, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Fuzeon Generics:
There are no approved generic versions for Fuzeon as of now.
Alternative Brands for Fuzeon
Fuzeon which is used for managing HIV infection., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||
|---|---|---|---|---|---|---|---|---|
| Agouron Pharms |
| |||||||
| Bristol Myers Squibb |
| |||||||
| Gilead |
| |||||||
| Gilead Sciences Inc |
| |||||||
| Viiv Hlthcare |
| |||||||
About Fuzeon
Fuzeon is a drug owned by Hoffmann La Roche Inc. It is used for managing HIV infection. Fuzeon uses Enfuvirtide as an active ingredient. Fuzeon was launched by Roche in 2003.
Approval Date:
Fuzeon was approved by FDA for market use on 13 March, 2003.
Active Ingredient:
Fuzeon uses Enfuvirtide as the active ingredient. Check out other Drugs and Companies using Enfuvirtide ingredient
Treatment:
Fuzeon is used for managing HIV infection.
Dosage:
Fuzeon is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 90MG/VIAL | INJECTABLE | Prescription | SUBCUTANEOUS |